跳至主要内容
临床试验/NCT00234728
NCT00234728已完成不适用

An Open-Label, Bilaterally-Controlled Single Center Study to Compare the Efficacy of Occlusion of Topical Agents With a Hydrophilic Occlusive Dressing to Treatment With Occlusive Dressing Without the Addition of Topical Agents

Teikoku Pharma USA, Inc.2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2005年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
120
试验地点
2
主要终点
Efficacy of topical medications with new occlusive dressing at baseline, weeks 2, 4, 6, 8.

研究概览

简要总结

The purpose of this study is to determine if a new dressing designed to be used with topical medications will enhance the effects of these topical medications.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject has signed the informed consent form and HIPAA authorization form
  • Male or female subject at least 18 years of age
  • A diagnosis of stable plaque-type psoriasis vulgaris with at least one "mirror image" pair of symmetric lesions on either the trunk, arms, or legs that would serve as target lesions. Paired target lesions must be in similar anatomic locations (e.g., right and left elbows or right and left knees) and have roughly equal (no more than one point difference) modified PASI scores. Both paired target lesions must have PASI scores equal to or greater than 1.5
  • Any additional diagnoses must, in the investigator's opinion, not preclude the subject from safely participating in this study or interfere with the evaluation of the subject's psoriasis
  • Psoriasis must be clinically stable for at least 30 days before enrollment
  • Subject is able to completely discontinue the use of any medication or therapy for relief of psoriasis in the target areas to be treated
  • Subject is able to completely discontinue the use of any systemic medication or therapy (e.g. oral or injectable psoriasis medications, PUVA phototherapy, herbal remedies, or acupuncture) for relief of psoriasis
  • Female subjects must be postmenopausal (defined as one year without menses), physically incapable of becoming pregnant, or using an acceptable birth control method. Acceptable methods of birth control include hormonal contraceptives or double-barrier methods (condom, diaphragm with spermicidal agent or IUD). If practicing an acceptable method of birth control, the subject must have confirmation of a negative urine pregnancy test at Screening
  • Subject must be reliable and mentally competent to complete study measurements
  • Subject is able to understand and agrees to comply with study requirements, attend study visits, and comply with the restrictions during the study.

排除标准

  • Subject has a skin disorder other than psoriasis in the target areas to be evaluated
  • Known hypersensitivity to any component of the test medications
  • Pigmentation, extensive scarring, or pigmented lesions in affected areas that would interfere with evaluation of efficacy parameters
  • Clinically infected psoriasis at baseline
  • Subject is pregnant or nursing
  • Guttate, pustular, erythrodermic, or other non-plaque forms of psoriasis
  • Spontaneously worsening or improving psoriasis within 30 days of enrollment
  • Any evidence of atrophy in the areas selected for treatment with topical corticosteroid
  • History of treating potential target lesions differently from one another
  • Topical or intralesional therapies (other than emollients) or UVB phototherapy on potential target lesions within two weeks of starting study treatment
  • Systemic therapy, PUVA phototherapy, or a systemic investigational therapy for psoriasis within 30 days prior to study entry
  • Treatment with topical investigational therapy of the target lesions within 30 days prior to study entry
  • Subject is considered unreliable as to medication compliance or adherence to scheduled appointments as determined by the investigators.

结局指标

主要结局

Efficacy of topical medications with new occlusive dressing at baseline, weeks 2, 4, 6, 8.

次要结局

  • Efficacy with new occlusive dressing alone without topical medications at baseline, weeks 2, 4, 6, 8.

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验